Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) following "home run with the 12-month data"
Tweet Send to a Friend
Mizuho analyst Uy Ear reiterated an Outperform rating and $10.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
